Holen Sie sich die Stockscreener-App
33.87
4.48%
-1.59
Handel nachbörslich:
33.89
0.02
+0.06%
Schlusskurs vom Vortag:
$35.46
Offen:
$35.16
24-Stunden-Volumen:
15.60M
Relative Volume:
0.72
Marktkapitalisierung:
$7.71B
Einnahmen:
$1.78B
Nettoeinkommen (Verlust:
$164.40M
KGV:
49.09
EPS:
0.69
Netto-Cashflow:
$236.51M
1W Leistung:
+4.31%
1M Leistung:
-13.42%
6M Leistung:
-30.82%
1J Leistung:
+31.64%
1-Tages-Spanne:
$33.51
$35.16
1-Wochen-Bereich:
$32.05
$36.45
52-Wochen-Spanne:
$23.97
$72.98
Hims Hers Health Inc Stock (HIMS) Company Profile
Firmenname
Hims Hers Health Inc
Sektor
Telefon
415-851-0195
Adresse
2269 CHESTNUT ST, SAN FRANCISCO
Vergleichen Sie HIMS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HIMS
Hims Hers Health Inc
|
33.87 | 8.07B | 1.78B | 164.40M | 236.51M | 0.69 |
|
ZTS
Zoetis Inc
|
126.85 | 55.38B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
16.37 | 50.23B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
10.04 | 44.75B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.51 | 37.17B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
UTHR
United Therapeutics Corp
|
490.83 | 21.69B | 3.08B | 1.24B | 1.07B | 25.61 |
Hims Hers Health Inc Stock (HIMS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-09 | Eingeleitet | Barclays | Overweight |
| 2025-10-21 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2025-06-23 | Herabstufung | Needham | Buy → Hold |
| 2025-06-04 | Bestätigt | Needham | Buy |
| 2025-04-29 | Herabstufung | TD Cowen | Buy → Hold |
| 2025-02-18 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-01-10 | Herabstufung | Citigroup | Neutral → Sell |
| 2025-01-07 | Eingeleitet | BTIG Research | Buy |
| 2024-12-17 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-11-14 | Herabstufung | BofA Securities | Buy → Underperform |
| 2024-08-22 | Eingeleitet | Needham | Buy |
| 2024-08-09 | Herabstufung | Imperial Capital | Outperform → In-line |
| 2024-05-22 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-04-16 | Herabstufung | Jefferies | Buy → Hold |
| 2024-04-10 | Eingeleitet | Canaccord Genuity | Buy |
| 2024-02-28 | Hochstufung | Imperial Capital | In-line → Outperform |
| 2024-02-26 | Eingeleitet | Leerink Partners | Market Perform |
| 2023-12-07 | Eingeleitet | Imperial Capital | In-line |
| 2023-07-28 | Eingeleitet | TD Cowen | Outperform |
| 2023-04-11 | Eingeleitet | Robert W. Baird | Neutral |
| 2023-02-09 | Hochstufung | Jefferies | Hold → Buy |
| 2022-11-08 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-11-08 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2022-10-17 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-09-07 | Eingeleitet | Truist | Hold |
| 2022-07-15 | Eingeleitet | SVB Leerink | Underperform |
| 2022-04-14 | Eingeleitet | Guggenheim | Buy |
| 2022-04-01 | Fortgesetzt | Credit Suisse | Outperform |
| 2022-03-10 | Eingeleitet | Deutsche Bank | Hold |
| 2021-12-02 | Eingeleitet | Jefferies | Hold |
| 2021-11-11 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-07-06 | Eingeleitet | BofA Securities | Neutral |
| 2021-05-20 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2021-04-21 | Eingeleitet | Truist | Hold |
| 2021-03-09 | Eingeleitet | Credit Suisse | Neutral |
| 2021-03-02 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-02-17 | Eingeleitet | Citigroup | Neutral |
| 2021-02-12 | Eingeleitet | Piper Sandler | Neutral |
| 2021-02-08 | Eingeleitet | Tigress Financial | Buy |
Alle ansehen
Hims Hers Health Inc Aktie (HIMS) Neueste Nachrichten
Hims & Hers Growth Story Has A Lot To Prove In 2026 (NYSE:HIMS) - Seeking Alpha
Hims & Hers Plunges 39.2% in 3 Months: Time to Hold the Stock or Sell? - The Globe and Mail
Hims & Hers: Looking Beyond GLP-1s To The Next Phase Of Global Growth (NYSE:HIMS) - Seeking Alpha
2026: The Year of the Consumer in Healthcare - Hims & Hers Newsroom
HIMS Stock Falls after BofA Slashes Price Target to a Street-Low of $29 - TipRanks
BofA Securities lowers Hims and Hers stock price target on 2026 investment concerns By Investing.com - Investing.com UK
Hims & Hers Enters 2026 On Solid Ground — Stock Rises Even After Novo Nordisk Leaves It Off Wegovy Partner List - Stocktwits
Hims & Hers Health: Under-Appreciated Upside (NYSE:HIMS) - Seeking Alpha
Hims & Hers: A Rare GARP Setup After The Market Reset (NYSE:HIMS) - Seeking Alpha
Hims & Hers: Capitalizing On Robust Subscriber/ARPU GrowthUpgraded Buy Rating (NYSE:HIMS) - Seeking Alpha
Hims & Hers Stock Defies Analyst Concerns with Strategic Pivot - AD HOC NEWS
Hims & Hers Health, Inc. (HIMS) Rises Higher Than Market: Key Facts - Yahoo Finance
Hims & Hers Health: Could Start To Look Interesting In 2026 (NYSE:HIMS) - Seeking Alpha
3 Stocks That May Be Trading Below Their Estimated Value - simplywall.st
Hims & Hers Health Is Building A Hormonal Empire (NYSE:HIMS) - Seeking Alpha
Hims & Hers enters 2026 on solid ground — stock rises even after Novo Nordisk leaves it off Wegovy partner list - MSN
How strong is Hims Hers Health Inc stock revenue growthJuly 2025 Review & Stock Market Timing Techniques - moha.gov.vn
Best Healthcare Stocks To ConsiderJanuary 5th - MarketBeat
Hims & Hers Expands Data-Driven, AI-Enabled Care and Personalization - Nasdaq
Hims & Hers: A Great Moment To Buy The Dip (NYSE:HIMS) - Seeking Alpha
Hims & Hers Health Inc. Stock (HIMS) Opinions on Canadian Market Expansion - Quiver Quantitative
Promising Healthcare Stocks To Keep An Eye OnJanuary 4th - MarketBeat
Healthcare Stocks To ConsiderJanuary 1st - MarketBeat
Promising Healthcare Stocks To ConsiderJanuary 3rd - MarketBeat
Hims & Hers Health (NYSE:HIMS) Seems To Use Debt Rather Sparingly - simplywall.st
Best Healthcare Stocks To Watch NowJanuary 2nd - MarketBeat
The Biomarker Blood Testing Gold Rush Is Here - Athletech News
HIMS Stock On A Losing Spree: Here's Why - Forbes
Market Sentiment Sours for Hims & Hers Shares - AD HOC NEWS
Mixed options sentiment in Hims and Hers Health with shares down 2.47% - Yahoo Finance
2 Russell 2000 Stocks Worth Investigating and 1 We Avoid - Finviz
HIMS Stock Falls -8.7% With A 7-day Losing Spree On Valuation Concerns - Trefis
How Hims & Hers Health Inc. Class A (HIMS) Affects Rotational Strategy Timing - Stock Traders Daily
Best Healthcare Stocks Worth WatchingDecember 28th - MarketBeat
Healthcare Stocks To Watch TodayDecember 31st - MarketBeat
Unpacking the Latest Options Trading Trends in Hims & Hers Health - Benzinga
Hims & Hers stock dips in premarket as GLP-1 drug pricing pressure stays in focus - ts2.tech
Hims & Hers Faces Investor Scrutiny Amid Profitability Concerns - AD HOC NEWS
Hims & Hers Health, Inc. (HIMS) Dips More Than Broader Market: What You Should Know - sharewise.com
Notable Tuesday Option Activity: Z, UPS, HIMS - Nasdaq
Best Healthcare Stocks To Watch TodayDecember 30th - MarketBeat
HIMS Scales AI-Enabled Care as Platform Depth and Engagement Expand - Yahoo Finance
Hims Delivered 173% Returns Over Five Years but Recent Buyers Face 50% Losses - AOL.com
Hims & Hers Health (HIMS) Fell Due to Increased Regulatory Challenges - Insider Monkey
Hims & Hers Health Stock (HIMS) Opinions on Canadian Market Expansion - Quiver Quantitative
Why Hims & Hers Health (HIMS) Is Rallying Today - MSN
Top 10 Most Shorted Stocks: Lucid, MARA, Hims and More - Benzinga
TEM vs. HIMS: Which Medical Info Systems Stock Offers Greater Upside - Finviz
Hims & Hers stock slides into year-end as investors weigh Ohio buildout and macro calendar - ts2.tech
Returns Recap: Why hedge funds are buying Hims Hers Health Inc stockBuy Signal & Expert Approved Momentum Ideas - moha.gov.vn
Hims & Hers: A Growth Story Battling Market Skepticism - AD HOC NEWS
Finanzdaten der Hims Hers Health Inc-Aktie (HIMS)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.41%
1.75%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):